全文获取类型
收费全文 | 12630篇 |
免费 | 556篇 |
国内免费 | 93篇 |
专业分类
耳鼻咽喉 | 119篇 |
儿科学 | 212篇 |
妇产科学 | 209篇 |
基础医学 | 1562篇 |
口腔科学 | 350篇 |
临床医学 | 809篇 |
内科学 | 3204篇 |
皮肤病学 | 304篇 |
神经病学 | 947篇 |
特种医学 | 542篇 |
外科学 | 1966篇 |
综合类 | 61篇 |
一般理论 | 1篇 |
预防医学 | 369篇 |
眼科学 | 321篇 |
药学 | 873篇 |
中国医学 | 44篇 |
肿瘤学 | 1386篇 |
出版年
2023年 | 63篇 |
2022年 | 131篇 |
2021年 | 245篇 |
2020年 | 120篇 |
2019年 | 170篇 |
2018年 | 240篇 |
2017年 | 185篇 |
2016年 | 233篇 |
2015年 | 277篇 |
2014年 | 325篇 |
2013年 | 411篇 |
2012年 | 636篇 |
2011年 | 744篇 |
2010年 | 467篇 |
2009年 | 379篇 |
2008年 | 638篇 |
2007年 | 710篇 |
2006年 | 680篇 |
2005年 | 741篇 |
2004年 | 674篇 |
2003年 | 724篇 |
2002年 | 716篇 |
2001年 | 330篇 |
2000年 | 295篇 |
1999年 | 310篇 |
1998年 | 192篇 |
1997年 | 160篇 |
1996年 | 153篇 |
1995年 | 98篇 |
1994年 | 109篇 |
1993年 | 99篇 |
1992年 | 204篇 |
1991年 | 174篇 |
1990年 | 160篇 |
1989年 | 163篇 |
1988年 | 124篇 |
1987年 | 137篇 |
1986年 | 124篇 |
1985年 | 106篇 |
1984年 | 81篇 |
1983年 | 59篇 |
1982年 | 40篇 |
1981年 | 45篇 |
1980年 | 39篇 |
1979年 | 83篇 |
1978年 | 60篇 |
1977年 | 46篇 |
1975年 | 37篇 |
1974年 | 34篇 |
1969年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Natural course of cavernous hepatic hemangioma 总被引:3,自引:0,他引:3
Okano H Shiraki K Inoue H Ito T Yamanaka T Deguchi M Sugimoto K Sakai T Ohmori S Murata K Takase K Nakano T 《Oncology reports》2001,8(2):411-414
Cavernous hepatic hemangiomas are benign liver tumors and present as incidental findings on sonographic examinations, but little is known concerning their natural course. Therefore, we performed a clinical and imaging follow-up of 64 cases of cavernous hepatic hemangioma in 50 patients during an average 18.8 month period. One case presented a symptom of slightly right upper quadrant pain and two cases showed thrombocytopenia. In one of the thrombocytopenia cases, cavernous hepatic hemangioma was resected because of Kasabach-Merrit syndrome. No case increased in size during follow-up, but one case decreased and disappeared. These results suggested that prolonged clinical and imaging follow-up of cavernous hepatic hemangiomas may be needed. 相似文献
992.
Murata M Watanabe M Yamanaka M Kubota Y Ito H Nagao M Katoh T Kamataki T Kawamura J Yatani R Shiraishi T 《Cancer letters》2001,165(2):171-177
Associations between genetic polymorphisms of CYP1A1, CYP1A2, CYP2E1, GSTM1 and GSTT1 and prostate cancer (PCa) were analyzed in a case-control study of 315 individuals. The frequency of valine (Val)/valine (Val) genotypes for CYP1A1 was 11.3% in cases compared with 5.5% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (odds ratio=2.4, 95% confidence interval (CI)=1.01-5.57). No links were detected between PCa and polymorphisms in other enzymes. However, the combination of CYP1A1 (Ile/Val and/or Val/Val) polymorphisms with the GSTM1 null type resulted in an OR of 2.2 (CI=1.10-4.57, 1.12-4.20, respectively). This study suggests that the CYP1A1 polymorphism and its combination with GSTM1 may be associated with PCa susceptibility in the Japanese population. 相似文献
993.
994.
M Tanaka H Kanamori S Yamaji A Mishima H Fujita S Fujisawa T Murata H Koharazawa M Matsuzaki H Mohri 《Anti-cancer drugs》1999,10(3):289-291
We report a 49-year-old female patient with secondary myelodysplastic syndrome who developed liver dysfunction and acute renal failure caused by low-dose cytosine arabinoside (Ara-C) therapy. Treatment of low-dose Ara-C has widely been used for acute myelogeous leukemia and myelodysplastic syndrome, and it is thought to be a low toxicity except for myelosuppression. The patient complained of a transient adverse reaction in the second and third course of therapy. This rare case indicates that careful observation should be carried out during low-dose Ara-C therapy in view of allergic reactions. 相似文献
995.
K Kusuzaki H Takeshita H Murata M Hirata S Hashiguchi T Ashihara Y Hirasawa 《Cancer letters》1999,141(1-2):131-138
We analyzed the DNA ploidy alterations after preoperative chemotherapy in 30 patients with non-metastatic osteosarcomas of the extremities. All of the patients received intensive chemotherapy with doxorubicin, cisplatin and methotrexate as well as wide tumor resection. DNA ploidy was determined by DNA cytofluorometry using isolated and smeared cells from biopsied and resected tumors after preoperative chemotherapy. The results showed that 12 diploid and nine non-diploid osteosarcomas did not change their ploidy pattern, but nine non-diploid tumors changed to a diploid pattern with the disappearance of the aneuploid cells. The nine patients with altered ploidy tumors had a better histologic response to chemotherapy and a better prognosis than the patients with non-altered tumors especially diploid tumors (P = 0.0138). Therefore, we conclude that a decrease in aneuploid cells after chemotherapy is closely correlated with a good prognosis in half of the cases of aneuploid osteosarcoma. These results also suggest that aneuploid cells are more chemosensitive than diploid cells in human osteosarcomas. 相似文献
996.
K Kusuzaki H Takeshita H Murata M Hirata S Hashiguchi T Ashihara Y Hirasawa 《Cancer letters》1999,137(1):27-33
In this study, we analysed the DNA ploidy of osteosarcomas at biopsy and attempted to clarify the relationship between DNA ploidy pattern and prognosis. Thirty patients with non-metastatic osteosarcoma of an extremity were studied. All underwent intensive chemotherapy with doxorubicin, cisplatin and methotrexate, in addition to wide tumor resection. DNA ploidy was detected by DNA cytofluorometry, using isolated and smeared cells of biopsied tumor tissue. Twelve tumors showed a diploid ploidy pattern and 18 showed a non-diploid pattern such as aneuploidy (15 tumors) and euploid-polyploidy (3 tumors). The event-free survival rate at 9 years was 63.5% in non-diploid osteosarcoma patients and 13.3% in diploid osteosarcoma patients. There was a statistically significant difference between the two groups (P = 0.0278). These results lead us to conclude that a non-diploid osteosarcoma may be more sensitive to chemotherapy than a diploid tumor. 相似文献
997.
Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer 总被引:1,自引:0,他引:1
Ishida H Fujioka M Takeuchi I Nakada H Kondo K Kishi T Inokuma S Suzuki T Yamada H Odaka A Shimomura K Murata N Idezuki Y Kamano T Matsumoto Y Miura T 《Gan to kagaku ryoho. Cancer & chemotherapy》1999,26(12):1690-1693
Preliminary results of a prospective non-randomized trial of prophylactic hepatic arterial chemotherapy for liver metastases from colorectal cancer are presented. Twenty-two colorectal cancer patients (infusion group) in Dukes' C stage were given hepatic arterial infusion of 5-FU (500 mg/body for 1 hr per week, repeated 50 times) and peroral UFT-E (2.0 g/body, daily). Informed consent was obtained from all patients. Adverse effects and postoperative recurrence in the infusion group were compared with those of patients with UFT-E alone (control group). Complications related to hepatic arterial infusion in the infusion group were also demonstrated. There was no adverse effect in the control group, while diarrhea (grade 1) developed in one patient (5%) and pigmentation in five (24%) in the infusion group. Complications related to infusion were found in five patients (5%). Three patients in the infusion group presented with metachronous hepatic lesions, two of which were resected successfully. In the control group, one patient died of marked hepatic metastases, and one developed ovarian metastasis with lymph node involvement. Our regimen appears hematologically safe, however, the high frequency of pigmentation should be kept in mind. The oncological benefit of this chemotherapy would be clarified by a larger series of cases and longer follow-up. 相似文献
998.
Blood flow influences vascular growth during tumour angiogenesis 总被引:6,自引:0,他引:6
Many factors play a role in tumour angiogenesis. We observed growing tumour vessels in vivo to study the relationship between blood flow and vascular enlargement. Mammary adenocarcinoma was implanted into Fisher-344 rat with dorsal skin-fold transparent chambers. Vascular growth was observed and recorded on videotape through a microscope for 6 h. Vascular networks were photographed and traced every 30 min to identify changes over time. Tumour sections were stained with Masson's trichrome and anti-Factor VIII-related antigen. Tumour growth was rapid enough for differences to be seen each hour. Vessels with a high blood flow showed an increase in diameter within a few hours and new branches formed from these vessels. In contrast, vessels without an increase in blood flow showed no change in diameter. Vessels within the interstitium surrounding the tumour were lined by endothelium that was positive for anti-Factor VIII-related antigen staining. Vessels in the tumour had extremely rare endothelial cells detectable by Masson's trichrome or anti-Factor VIII-related antigen staining. In conclusion, increased blood flow may cause vascular enlargement and some primitive vessels seem to lack endothelium. 相似文献
999.
Murata J Ayukawa K Ogasawara M Watanabe H Saiki I 《International journal of cancer. Journal international du cancer》1999,80(6):889-895
We have previously reported that neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) successfully inhibited Matrigel invasion and haptotactic migration of B16-BL6 melanoma cells towards both fibronectin and laminin without affecting their growth. In the present study, we investigated the inhibitory mechanism of tumor cell motility by alpha-MSH. Alpha-MSH significantly blocked the autocrine motility factor (AMF)-enhanced cell motility. However, alpha-MSH did neither prevent the secretion of AMF from B16-BL6 cells nor alter the expression level of AMF receptor (gp78). On the other hand, alpha-MSH induced the secretion of the motility inhibitory factor(s) from B16-BL6 cells in a concentration- and time-dependent manner. The induction of the motility inhibitor(s) was proportional to increasing levels of intracellular cAMP induced by alpha-MSH as well as forskolin, and the activity was abolished by an adenylate cyclase inhibitor, 2',5'-dideoxyadenosine (DDA). The motility-inhibiting activity in conditioned medium (CM) from alpha-MSH-treated B16-BL6 cells was found to have a m.w. below 3 kDa after fractionation. This activity was abolished by boiling but insensitive to trypsin. The treatment of tumor cells with cycloheximide reduced the activity in alpha-MSH-stimulated CM. Our results suggest that alpha-MSH inhibited the motility of B16-BL6 cells through induction of autocrine factor(s). 相似文献
1000.
Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma 总被引:2,自引:0,他引:2
Kanno H Hattori S Sato H Murata H Huang FH Hayashi A Suzuki N Yamamoto I Kawamoto S Minami M Miyatake S Shuin T Kaplitt MG 《Cancer gene therapy》1999,6(2):147-154
We investigated the feasibility of local treatment or tumor vaccination with a herpes simplex virus (HSV) type 1-defective vector. The vector was engineered to express murine interferon-gamma (IFN-gamma) for experimental gene therapy against mouse glioma Rous sarcoma virus (RSV). The murine IFN-gamma gene was driven by the cytomegalovirus promoter. The helper virus (tsk) was thermosensitive; consequently, this vector could only proliferate at 31 degrees C. A high level of murine IFN-gamma expression was confirmed in vitro and in vivo by immunohistochemistry using anti-mouse IFN-gamma monoclonal antibody. This engineered vector (dvHSV/MulFN-gamma) inhibited the proliferation of mouse glioma RSV cells in vitro, and an intratumoral (i.t.) local injection of the vector caused i.t. necrosis in vivo. The immunological effect of dvHSV/MulFN-gamma was also examined in a mouse glioma RSV cell implantation model. A subcutaneous (s.c.) implant of 1 x 10(6) mouse glioma RSV cells after treatment with dvHSV/MulFN-gamma was rejected. However, the implant after treatment with an engineered HSV-defective vector containing an antisense nucleotide sequence of the murine IFN-gamma gene was not rejected. In addition, in another group of mice in which RSV cells treated with dvHSV/MulFN-gamma were implanted into a femoral (s.c.) region and nontreated RSV cells were implanted into a contralateral femoral (s.c.) region, the implanted RSV cells were rejected. The rejection of the implanted mouse glioma RSV was blocked by anti-asialo GM1, which was known to inhibit natural killer cell activity. These results revealed that the HSV-defective vector could realize a high efficiency of transfection to glioma cells through short-time treatment, and that the IFN-gamma gene transferred to the cells had the effect of tumor vaccination, which was suggested be related to natural killer cells. In conclusion, dvHSV/MulFN-gamma may be useful for the gene therapy of malignant glioma through either i.t. local injection or a practical tumor vaccination with ex vivo gene transfer. 相似文献